{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:09:36Z","timestamp":1782468576454,"version":"3.54.5"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T00:00:00Z","timestamp":1713571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009192","name":"Alberta Innovates","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018911","name":"University Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000190","name":"Universities of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007582","name":"Alberta Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010090","name":"Woman and Children\u2019s Health Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Determining the frequency and outcomes of neurological disorders associated with coronavirus disease 2019 (COVID-19) is imperative for understanding risks and for recognition of emerging neurological disorders. We investigated the susceptibility and impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among persons with premorbid neurological disorders, in addition to the post-infection incidence of neurological sequelae, in a case\u2013control population-based cohort.<\/jats:p>\n               <jats:p>Using health service data collected between 1 March 2020 and 30 June 2021, we constructed a cohort of SARS-CoV-2 RNA-positive (n = 177 892) and -negative (n = 177 800) adults who were age, sex and comorbidity matched and underwent RT-PCR testing at similar times. COVID-19-associated mortality rates were examined within the cohort. Neurological sequelae were analysed during the acute (&amp;lt;3 months) and the post-acute (3\u20139 months) phases post-infection.<\/jats:p>\n               <jats:p>The risk of death was significantly greater in the SARS-CoV-2 RNA-positive (2140 per 100 000 person years) compared with RNA-negative (922 per 100 000 person years) over a follow-up of 9 months, particularly amongst those with premorbid neurological disorders: adjusted odds ratios (95% confidence interval) in persons with a prior history of parkinsonism, 1.65 (1.15\u20132.37); dementia, 1.30 (1.11\u20131.52); seizures, 1.91 (1.26\u20132.87); encephalopathy, 1.82 (1.02\u20133.23); and stroke, 1.74 (1.05\u20132.86). There was also a significantly increased risk for diagnosis of new neurological sequelae during the acute time phase after COVID-19, including encephalopathy, 2.0 (1.10\u20133.64); dementia, 1.36 (1.07\u20131.73); seizure, 1.77 (1.22\u20132.56); and brain fog, 1.96 (1.20\u20133.20). These risks persisted into the post-acute phase after COVID-19, during which inflammatory myopathy (2.57, 1.07\u20136.15) and coma (1.87, 1.22\u20132.87) also became significantly increased.<\/jats:p>\n               <jats:p>Thus, persons with SARS-CoV-2 infection and premorbid neurological disorders are at greater risk of death, and SARS-CoV-2 infection was complicated by increased risk of new-onset neurological disorders in both the acute and post-acute phases of COVID-19.<\/jats:p>","DOI":"10.1093\/brain\/awae117","type":"journal-article","created":{"date-parts":[[2024,4,20]],"date-time":"2024-04-20T02:50:40Z","timestamp":1713581440000},"page":"2542-2551","source":"Crossref","is-referenced-by-count":10,"title":["Increased frequency and mortality in persons with neurological disorders during COVID-19"],"prefix":"10.1093","volume":"147","author":[{"given":"Candace M","family":"Marsters","sequence":"first","affiliation":[{"name":"Division of Neurology, Department of Medicine, University of Alberta , Edmonton, AB T6G 2B7 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Bakal","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, University of Alberta , Edmonton, AB T6G 2B7 , Canada"},{"name":"Provincial Research Data Services-Alberta Health Services , Edmonton, AB T6G 2B7 , Canada"},{"name":"Alberta Strategy for Patient Oriented Research Unit , Edmonton, AB T6G 2C8 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Y","family":"Lam","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Department of Medicine, University of Alberta , Edmonton, AB T6G 2B7 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finlay A","family":"McAlister","sequence":"additional","affiliation":[{"name":"Alberta Strategy for Patient Oriented Research Unit , Edmonton, AB T6G 2C8 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5131-9711","authenticated-orcid":false,"given":"Christopher","family":"Power","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, University of Alberta , Edmonton, AB T6G 2B7 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,20]]},"reference":[{"key":"2024070507220967100_awae117-B1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41586-022-05542-y","article-title":"SARS-CoV-2 infection and persistence in the human body and brain at autopsy","volume":"612","author":"Stein","year":"2022","journal-title":"Nature"},{"key":"2024070507220967100_awae117-B2","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/brain\/awab302","article-title":"Acute and chronic neurological disorders in COVID-19: Potential mechanisms of disease","volume":"144","author":"Balcom","year":"2021","journal-title":"Brain"},{"key":"2024070507220967100_awae117-B3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.parkreldis.2022.04.011","article-title":"Parkinson\u2019s disease related mortality: Long-term trends and impact of COVID-19 pandemic waves","volume":"98","author":"Fedeli","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"key":"2024070507220967100_awae117-B4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/08850666211001799","article-title":"Clinical features and risk factors for in-hospital mortality from COVID-19 infection at a tertiary care medical center, at the onset of the US COVID-19 pandemic","volume":"36","author":"Bhargava","year":"2021","journal-title":"J Intensive Care Med"},{"key":"2024070507220967100_awae117-B5","doi-asserted-by":"crossref","first-page":"e0260381","DOI":"10.1371\/journal.pone.0260381","article-title":"Risk factors for excess all-cause mortality during the first wave of the COVID-19 pandemic in England: A retrospective cohort study of primary care data","volume":"16","author":"Carey","year":"2021","journal-title":"PLoS One"},{"key":"2024070507220967100_awae117-B6","doi-asserted-by":"crossref","first-page":"e1003870","DOI":"10.1371\/journal.pmed.1003870","article-title":"Factors associated with excess all-cause mortality in the first wave of the COVID-19 pandemic in the UK: A time series analysis using the clinical practice research datalink","volume":"19","author":"Strongman","year":"2022","journal-title":"PLoS Med"},{"key":"2024070507220967100_awae117-B7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.seizure.2021.11.017","article-title":"Epilepsy mortality in Wales during COVID-19","volume":"94","author":"Daniels","year":"2022","journal-title":"Seizure"},{"key":"2024070507220967100_awae117-B8","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1212\/WNL.0000000000011611","article-title":"A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York city","volume":"96","author":"Frontera","year":"2021","journal-title":"Neurology"},{"key":"2024070507220967100_awae117-B9","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/ene.15293","article-title":"Short- and long-term outcome and predictors in an international cohort of patients with neuro-COVID-19","volume":"29","author":"Beghi","year":"2022","journal-title":"Eur J Neurol"},{"key":"2024070507220967100_awae117-B10","doi-asserted-by":"crossref","first-page":"e0686","DOI":"10.1097\/CCE.0000000000000686","article-title":"Neurologic manifestations of severe acute respiratory syndrome coronavirus 2 infection in hospitalized patients during the first year of the COVID-19 pandemic","volume":"4","author":"Cervantes-Arslanian","year":"2022","journal-title":"Crit Care Explor"},{"key":"2024070507220967100_awae117-B11","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1093\/brain\/awac332","article-title":"Neurological manifestations of COVID-19 in adults and children","volume":"146","author":"Cho","year":"2023","journal-title":"Brain"},{"key":"2024070507220967100_awae117-B12","doi-asserted-by":"crossref","first-page":"e1060","DOI":"10.1212\/WNL.0000000000009937","article-title":"Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry","volume":"95","author":"Romero-S\u00e1nchez","year":"2020","journal-title":"Neurology"},{"key":"2024070507220967100_awae117-B13","doi-asserted-by":"crossref","first-page":"e2112131","DOI":"10.1001\/jamanetworkopen.2021.12131","article-title":"Global incidence of neurological manifestations among patients hospitalized with COVID-19\u2014A report for the GCS-NeuroCOVID consortium and the ENERGY consortium","volume":"4","author":"Chou","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2024070507220967100_awae117-B14","doi-asserted-by":"crossref","first-page":"101019","DOI":"10.1016\/j.eclinm.2021.101019","article-title":"Characterizing long COVID in an international cohort: 7 months of symptoms and their impact","volume":"38","author":"Davis","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2024070507220967100_awae117-B15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/ene.15617","article-title":"Comparative features and outcomes of major neurological complications of COVID-19","volume":"30","author":"Beghi","year":"2023","journal-title":"Eur J Neurol"},{"key":"2024070507220967100_awae117-B16","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/ene.14444","article-title":"Assessment of neurological manifestations in hospitalized patients with COVID-19","volume":"27","author":"Luigetti","year":"2020","journal-title":"Eur J Neurol"},{"key":"2024070507220967100_awae117-B17","doi-asserted-by":"crossref","first-page":"n1098","DOI":"10.1136\/bmj.n1098","article-title":"Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: Retrospective cohort study","volume":"373","author":"Daugherty","year":"2021","journal-title":"BMJ"},{"key":"2024070507220967100_awae117-B18","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1473-3099(21)00211-5","article-title":"Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: A Danish population-based cohort study","volume":"21","author":"Lund","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2024070507220967100_awae117-B19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S2215-0366(21)00084-5","article-title":"6-month neurological and psychiatric outcomes in 236,379 survivors of COVID-19: A retrospective cohort study using electronic health records","volume":"8","author":"Taquet","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"2024070507220967100_awae117-B20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S2215-0366(22)00260-7","article-title":"Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: An analysis of 2-year retrospective cohort studies including 1,284,437 patients","volume":"9","author":"Taquet","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"2024070507220967100_awae117-B21","doi-asserted-by":"crossref","first-page":"e0278057","DOI":"10.1371\/journal.pone.0278057","article-title":"Post-acute sequelae of COVID-19 among hospitalized patients in Estonia: Nationwide matched cohort study","volume":"17","author":"Tisler","year":"2022","journal-title":"PLoS One"},{"key":"2024070507220967100_awae117-B22","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/s41591-022-02001-z","article-title":"Long-term neurologic outcomes of COVID-19","volume":"28","author":"Xu","year":"2022","journal-title":"Nat Med"},{"key":"2024070507220967100_awae117-B23","doi-asserted-by":"crossref","first-page":"e072529","DOI":"10.1136\/bmj-2022-072529","article-title":"Long COVID outcomes at one year after mild SARS-CoV-2 infection: Nationwide cohort study","volume":"380","author":"Mizrahi","year":"2023","journal-title":"BMJ"},{"key":"2024070507220967100_awae117-B24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41591-022-02116-3","article-title":"Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes","volume":"29","author":"Zhang","year":"2023","journal-title":"Nat Med"},{"key":"2024070507220967100_awae117-B25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1126\/science.abm2052","article-title":"Nervous system consequences of COVID-19","volume":"375","author":"Spudich","year":"2022","journal-title":"Science"},{"key":"2024070507220967100_awae117-B26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12911-015-0155-5","article-title":"Methods for identifying 30 chronic conditions: Application to administrative data","volume":"15","author":"Tonelli","year":"2015","journal-title":"BMC Med Inform Decis Mak"},{"key":"2024070507220967100_awae117-B27","doi-asserted-by":"crossref","first-page":"e068414","DOI":"10.1136\/bmj-2021-068414","article-title":"Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: Retrospective cohort study","volume":"376","author":"Cohen","year":"2022","journal-title":"BMJ"},{"key":"2024070507220967100_awae117-B28","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1161\/CIRCULATIONAHA.120.050809","article-title":"Acute COVID-19 and the incidence of ischemic stroke and acute myocardial infarction","volume":"142","author":"Modin","year":"2020","journal-title":"Circulation"},{"key":"2024070507220967100_awae117-B29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/STROKEAHA.120.031668","article-title":"Acute cerebrovascular events with COVID-19 infection","volume":"52","author":"Dhamoon","year":"2021","journal-title":"Stroke"},{"key":"2024070507220967100_awae117-B30","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(21)00896-5","article-title":"Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: A self-controlled case series and matched cohort study","volume":"398","author":"Katsoularis","year":"2021","journal-title":"Lancet"},{"key":"2024070507220967100_awae117-B31","doi-asserted-by":"crossref","first-page":"e0261786","DOI":"10.1371\/journal.pone.0261786","article-title":"COVID-19 is associated with higher risk of venous thrombosis, but not arterial thrombosis, compared with influenza: Insights from a large US cohort","volume":"17","author":"Ward","year":"2022","journal-title":"PLoS One"},{"key":"2024070507220967100_awae117-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaneurol.2020.2730","article-title":"Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza","volume":"77","author":"Merkler","year":"2020","journal-title":"JAMA Neurol"},{"key":"2024070507220967100_awae117-B33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbi.2023.05.014","article-title":"Risks of neurological and psychiatric sequelae 2 years after hospitalisation or intensive care admission with COVID-19 compared to admissions for other causes","volume":"112","author":"Ley","year":"2023","journal-title":"Brain Behav Immun"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awae117\/58109774\/awae117.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/147\/7\/2542\/58447135\/awae117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/147\/7\/2542\/58447135\/awae117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T07:24:14Z","timestamp":1720164254000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/147\/7\/2542\/7654052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4,20]]},"published-print":{"date-parts":[[2024,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awae117","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,4,20]]}}}